Background: Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system. Diminished inflammatory disease activities (DAs) as people with MS (pwMS) age justified randomized clinical trials assessing disease-modifying therapy (DMT) discontinuation in older pwMS given the concern for risk outweighing benefit. Objective: This study aims to examine the effect of age on DAs and the peripheral production of Myelin Basic Protein (MBP)-driven cytokine response in pwMS. Methods: We included the clinical data of 368 adult pwMS between 2017 and 2021 from a clinic-based registry. In a subset of 80 participants, we isolated fresh peripheral blood mononuclear cells (PBMCs) and cultured with 50 μg/ml of MBP for 24 hours. We assayed cell culture supernatants for IL-17 and IFN-gamma; using Enzyme-Linked Immunosorbent Assay. We further analyzed a subset of the supernatant samples using the Luminex xMAP platform human cytokine/chemokine array. We examined associations between age and inflammatory DA [annualized relapse rate (ARR)] as well as age and MBP-stimulated cytokine production (by cultured PBMC) using covariate-adjusted linear regression. We determined the extent of the MBP-driven cytokine responses in driving the association between age and ARR using mediation analyses. Results: Among the 386 pwMS (mean age 53.1±12.6 years, 79.9% women, 92.1% non-Hispanic White), ARR declined with age (β=-0.003, p<0.001). Among the 80 pwMS with cultured PBMC, MBP-driven IL-17 production declined with age in women (β=-0.27, p=0.04) but not men (β=-0.1, p=0.73). MBP-driven IL-17 response partially mediated the association between older age and lower ARR (24.7% in women, 15.3% in men). Further, older pwMS (≥50 years) had significantly lower (IL-4, MCP2, MCP3, PDGF.AA, PDGF.AB.BB) and higher (Fractalkine, MDC) concentrations of several cytokines when compared to younger pwMS (<50 years). These cytokines affected the association between age and ARR in different ways, with some of them (MCP-2 and MDC) likely mediating the effect of age on ARR, while the others likely counteracting the effect of age on ARR. Conclusion: This study suggests some of the potential biological mechanisms driving aging-dependent decline in MS inflammatory DA.